Raab & Moskowitz Asset Management LLC Increases Stake in Pfizer Inc.

Raab & Moskowitz Asset Management LLC has recently boosted its investment in Pfizer Inc. (NYSE:PFE) by 8.5% during the third quarter of the year. This information was disclosed in the company’s latest Form 13F filing with the Securities and Exchange Commission (SEC). Following the acquisition of an additional 20,197 shares, Raab & Moskowitz now holds a total of 259,134 shares of the well-known biopharmaceutical company. Pfizer represents approximately 1.9% of the firm's overall portfolio, making it the 12th largest investment in their holdings. At the end of this reporting period, the worth of Raab & Moskowitz's holdings in Pfizer was valued at about $7,499,000.

Activity Among Other Investors

In recent times, other institutional investors and hedge funds have also adjusted their positions in Pfizer. For instance, Gladius Capital Management LP increased its stake in the company by a staggering 102.8% in the third quarter. They now possess 1,043 shares, worth $30,000, after acquiring 38,015 additional shares during this period. Similarly, MFA Wealth Advisors LLC initiated a new investment in Pfizer in the second quarter valued at approximately $29,000. Other notable purchases include Quarry LP, which invested about $31,000, and Financial Connections Group Inc. with an investment amounting to around $34,000. Additionally, during the third quarter, Teachers Insurance & Annuity Association of America purchased shares valued at approximately $35,000. Currently, institutional investors own around 68.36% of Pfizer's stock.

Analysts Update Price Targets

Several analysts have recently revised their price targets for Pfizer shares. On November 15, Wolfe Research started coverage on Pfizer and assigned it an “underperform” rating with a price target set at $25.00. StockNews.com lowered its rating on Pfizer from “strong-buy” to “buy” on November 20. Fortunately, Evercore ISI upgraded Pfizer to a “strong-buy” rating on October 30. Citigroup also initiated coverage with a “neutral” rating, giving a price target of $30.00 on October 25. Additionally, Cantor Fitzgerald maintained an “overweight” rating, setting a target price of $45.00. According to MarketBeat data, one analyst rated it as a sell, eight gave it a hold rating, while six assigned a buy rating, and two issued a strong buy rating, resulting in a consensus rating of “Moderate Buy” with a target price of $32.92.

Pfizer Stock Performance Overview

On Friday, shares of NYSE:PFE opened at $25.73. Over the past year, the stock hit a low of $24.48 and soared to a high of $31.54. Financially, the company has a current ratio of 1.00, a quick ratio of 0.73, and a debt-to-equity ratio of 0.63. Pfizer has a market capitalization of about $145.81 billion, with a price-to-earnings (P/E) ratio of 34.77, a P/E to growth (P/E/G) ratio of 0.68, and a beta of 0.65. The stock also shows a 50-day moving average of $27.47 and a 200-day moving average of $28.38.

Latest Quarterly Earnings

Pfizer released its quarterly earnings results recently on October 29. The biopharmaceutical firm reported earnings of $1.06 per share, exceeding the consensus estimate of $0.64 by $0.42. Revenues stood at $17.70 billion, compared to the anticipated $14.92 billion. Pfizer's net margin for the quarter was recorded at 7.07%, while the return on equity was 16.28%. Notably, the company experienced a year-over-year revenue increase of 31.2%. Analysts predict that Pfizer Inc. will report an earnings per share (EPS) of 2.95 for the current fiscal year.

Recent Dividend Declaration

Lastly, the company declared its most recent quarter dividend on December 2, with shareholders on record as of November 8 receiving a dividend payment of $0.42 per share. The ex-dividend date was also set for November 8, which leads to an annualized dividend of $1.68 and a dividend yield of 6.53%. Currently, the dividend payout ratio stands at a high 227.03%.

Insider Transactions

Regarding insider dealings, Scott Gottlieb, a director at Pfizer, bought 1,000 shares on October 30 at an average price of $28.24 per share, totaling $28,240. After this transaction, he holds about 10,000 shares, which are valued at approximately $282,400, representing an increase of 11.11% in his stake. This acquisition was reported and filed with the SEC. Currently, insiders hold about 0.06% of the company's stock.

About Pfizer

Pfizer Inc. is a global pharmaceutical corporation that discovers, develops, manufactures, markets, distributes, and sells various biopharmaceutical products. The company provides medications and vaccines across several therapeutic areas, including cardiovascular care, migraine treatment, and women’s health, with well-known brands like Eliquis and Nurtec ODT. They also focus on infectious diseases including COVID-19 treatment and prevention, utilizing products such as Comirnaty and Paxlovid.

investment, stocks, Pfizer